Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck’s Vytorin claims; Pacira settles off-label marketing case with the FDA
Five things for pharma marketers to know: Wednesday, December 9, 2015
Gilead criticized over Sovaldi pricing strategy; analysis finds branded drugs cost more in the US; support is growing for Medicare negotiation of drug prices
Five things for pharma marketers to know: Tuesday, November 24, 2015
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease
Five things for pharma marketers to know: Wednesday, November 18, 2015
Aggressive treatment of blood pressure reduces deaths; AstraZeneca’s experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
Five things for pharma marketers to know: Tuesday, November 3, 2015
GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development
Five things for pharma marketers to know: Tuesday, October 27, 2015
Novartis to pay $390 million to settle a lawsuit over drug sales; researchers examine why some patients respond better than others to immuno-oncology drugs; experimental heart-failure drug to get late-stage trial
Five things for pharma marketers to know: Tuesday, October 20, 2015
Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands
Five things for pharma marketers to know: Wednesday, October 14, 2015
J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix